BTM-3566 is an orally-available novel small molecule compound with broad anti-cancer activity in hematologic and solid tumors, initially focused on Diffuse Large B-cell Lymphomas (DLBCL).
In initial preclinical studies, BTM-3566 has shown exceptional in-vitro and in vivo activity against DLBCL, inducing rapid, durable, and complete remission in multiple tumor models.

An IND application for BTM-3566 in B-cell malignancies has been submitted and the phase 1 study allowed to proceed by FDA. Bantam is currently seeking its next round of investment to initiate this first-in-humans clinical trial.


There is extreme unmet need in relapsed/refractory DLBCL, where median survival is 7 months with existing standard of care therapy.
How BTM-3566 works
BTM-3566 targets mitochondrial dynamics leading to cellular stress and tumor cell apoptosis
  1. BTM-3566 induces activation of OMA1, causing cleavage of:
  2. Mitochondrial proteins OPA1 and DELE1
  3. This leads to activation of HRI Kinase and phosphorylation of eIF2a
  4. eIF2a regulates the Integrated Stress Response (ISR), triggering homeostasis adaption or apoptosis depending upon cellular context
BTM-3566 modulates mitochondrial dynamics leading to cellular stress, apoptosis and rapid tumor regression in varied models of lymphoma
We are an early mover in the field of mitochondrial homeostasis, using our pioneering science and unrivaled expertise in mitochondrial cellular biology to revolutionize oncology
We are seeking partners and additional investors to accelerate our clinical research and help bring novel cancer therapies closer to patients in need
Find Out More
Bantam is seeking partners and investors to drive rapid clinical development of our first-in-class molecule from First in Humans trials to clinical Proof of Concept.
Top linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram